An Open Letter to Fox Chase Staff and Friends

Fox Chase Board Elects Next Center President and CEO

March 22, 2007

I am pleased to announce that Fox Chase Cancer Center's board of directors has elected Michael V Seiden, MD, PhD, of Massachusetts General Hospital and Dana-Farber/Harvard Cancer Center to become president and chief executive officer of Fox Chase effective June 1. His selection came after a long and highly competitive national search that began last year when Robert C. Young, M.D., announced his intention to step down as president.

The search committee faced a hard challenge. Bob Young has guided Fox Chase with great vision and leaves us with a magnificent legacy. He has been a leader, a colleague and a friend. We congratulate him on his contributions to the Center and hope that after his sabbatical, he will continue to have a role both here and at a national level.

From the beginning of this search, we were fortunate to have a number of superlative candidates, in itself a tribute to the strength and vigor of Fox Chase Cancer Center. Narrowing the field and making the final choice was tremendously difficult, but we are delighted that Dr. Seiden has agreed to accept the position.

Michael Seiden is a strong visionary with a bold plan for Fox Chase. He is an individual who impresses everyone with the depth and breadth of his intellect and his willingness and ability to make decisions. His experience as a leader, clinician and scientist promises remarkable success for Fox Chase in the coming decades.

He is a compassionate clinician and an insightful scientist with an unwavering commitment to both patient care and cancer research that is matched by a keen business judgment. His passion for the abundant opportunities presented by new discoveries about cancer and new research and clinical technology assures that Fox Chase will continue to take the lead in innovative cancer treatment and prevention strategies and internationally acclaimed cancer research.

Dr. Seiden is a board-certified medical oncologist who currently leads the gynecologic cancer program at Dana-Farber/Harvard and is chief of the clinical research unit in Massachusetts General Hospital's division of cancer medicine. In addition, his present responsibilities include serving as associate professor of medicine at Harvard and physician coordinator of the cancer stem-cell project at Dana-Farber/Harvard Cancer Center.

The recruitment of such an outstanding individual is a stellar example of how a world-class cancer center can obtain the very best leaders. We welcome him to Fox Chase and to Philadelphia.


William J. Avery,
Chairman, Board of Directors


See also: